[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7436 Introduced in House (IH)]
<DOC>
118th CONGRESS
2d Session
H. R. 7436
To direct the Comptroller General of the United States to prepare a
report on Federal efforts to address antimicrobial resistance.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
February 23, 2024
Mr. Griffith introduced the following bill; which was referred to the
Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To direct the Comptroller General of the United States to prepare a
report on Federal efforts to address antimicrobial resistance.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Antimicrobial Resistance Research
Assessment Act of 2024''.
SEC. 2. REPORT ON FEDERAL EFFORTS TO ADDRESS ANTIMICROBIAL RESISTANCE.
(a) In General.--The Comptroller General of the United States
shall--
(1) prepare a report on efforts of the Federal Government
to address antimicrobial resistance; and
(2) not later than 1 year after the date of enactment of
this Act--
(A) finalize such report; and
(B) submit such report to the Congress.
(b) Contents.--The report required by subsection (a) shall--
(1) address all efforts of the Federal Government regarding
antimicrobial resistance, including any such efforts
involving--
(A) establishing, maintaining, or operating a task
force, committee, or interagency program; or
(B) developing a plan or report;
(2) specify the role of each Federal program and resource
in such efforts;
(3) identify any such efforts that are duplicative;
(4) recommend ways to improve the coordination of such
efforts across the Federal Government;
(5) identify the results achieved thus far through such
efforts;
(6) describe any such efforts related to phage therapy; and
(7) with respect to research being federally conducted or
supported with respect to antimicrobial resistance--
(A) quantify of the costs of such research;
(B) if any such research is identified as
duplicative pursuant to paragraph (3), recommend
approaches for coordinating or consolidating such
research to avoid duplication; and
(C) recommend whether there should be a central
Federal agency to oversee such research.
<all>